Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKesson
Boehringer Ingelheim
Medtronic
Moodys

Last Updated: August 15, 2022

EYSUVIS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Eysuvis, and what generic alternatives are available?

Eysuvis is a drug marketed by Kala Pharms Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has seventy-nine patent family members in twelve countries.

The generic ingredient in EYSUVIS is loteprednol etabonate. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Eysuvis

A generic version of EYSUVIS was approved as loteprednol etabonate by AKORN on April 17th, 2019.

  Try it Free

Summary for EYSUVIS
International Patents:79
US Patents:13
Applicants:1
NDAs:1
Clinical Trials: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for EYSUVIS
What excipients (inactive ingredients) are in EYSUVIS?EYSUVIS excipients list
DailyMed Link:EYSUVIS at DailyMed
Drug patent expirations by year for EYSUVIS
Drug Prices for EYSUVIS

See drug prices for EYSUVIS

Recent Clinical Trials for EYSUVIS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kala Pharmaceuticals, Inc.Phase 4
Price Vision GroupPhase 4

See all EYSUVIS clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for EYSUVIS

US Patents and Regulatory Information for EYSUVIS

EYSUVIS is protected by thirteen US patents and one FDA Regulatory Exclusivity.

Patents protecting EYSUVIS

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER

Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT

FDA Regulatory Exclusivity protecting EYSUVIS

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kala Pharms Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Kala Pharms Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Kala Pharms Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for EYSUVIS

See the table below for patents covering EYSUVIS around the world.

Country Patent Number Title Estimated Expiration
Japan 6816064 See Plans and Pricing
South Korea 20150006869 PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT See Plans and Pricing
South Korea 20210013339 PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Harvard Business School
Baxter
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.